Dr. Reddy's Laboratories Share PriceDr. Reddy's Laboratories

17.4 (0.37%)
  • Advice
  • Hold
As on 10 June, 2023 | 12:31 BSE: 500124 NSE: DRREDDY

Dr. Reddy's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Dr. Reddy's Laboratories

Start SIP

Dr. Reddy's Laboratories Share Price

  • Over 1 Month -5.4%
  • Over 3 Month 6.52%
  • Over 6 Month 5.89%
  • Over 1 Year 7.96%

Dr. Reddy's Laboratories Key Statistics

P/E Ratio 17.2
PEG Ratio 0.2
Market Cap Cr 77,723
Price to Book Ratio 3.3
EPS 156.9
Dividend 0.6
Relative Strength Index 55.59
Money Flow Index 62.32
MACD Signal -30.97
Average True Range 66.09

Dr. Reddy's Laboratories Investment Rating

  • Master Rating:
  • Dr. Reddy's Laboratories has an operating revenue of Rs. 24,669.70 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 24% is great, ROE of 19% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 6% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 52 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Dr. Reddy's Laboratories Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 4,2493,8984,8663,6163,632
Operating Expenses Qtr Cr 3,4893,2233,0783,0512,989
Operating Profit Qtr Cr 1,0616751,803580670
Depreciation Qtr Cr 237239226222205
Interest Qtr Cr 3321013
Tax Qtr Cr 264160577252147
Net Profit Qtr Cr 6723251,116500420

Dr. Reddy's Laboratories Technicals


Current Price
17.4 (0.37%)
  • Bullish Moving Average
  • ___
  • 15
  • Bearish Moving Average
  • ___
  • 1
  • 20 Day
  • ₹4606.01
  • 50 Day
  • ₹4614.16
  • 100 Day
  • ₹4564.72
  • 200 Day
  • ₹4496.19
  • 20 Day
  • ₹4538.57
  • 50 Day
  • ₹4690.45
  • 100 Day
  • ₹4547.04
  • 200 Day
  • ₹4441.12

Dr. Reddy's Laboratories Resistance and Support

First Resistance ₹4699.34
Second Resistance ₹4731.87
Third Resistance ₹4758.74
RSI 55.59
MFI 62.32
MACD Single Line -30.97
MACD -6.22
First Resistance ₹4639.94
Second Resistance ₹4613.07
Third Resistance ₹4580.54

Dr. Reddy's Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 220,925 14,285,011 64.66
Week 232,742 15,365,640 66.02
1 Month 487,155 26,194,334 53.77
6 Month 371,691 20,509,892 55.18

Dr. Reddy's Laboratories Result Highlights

Dr. Reddy's Laboratories Synopsis


Dr. Reddy's Labs is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 16962.50 Cr. and Equity Capital is Rs. 83.30 Cr. for the Year ended 31/03/2023. Dr. Reddy's Laboratories Ltd. is a Public Limited Listed company incorporated on 24/02/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004507 and registration number is 004507.
Market Cap 77,723
Sales 16,962
Shares in Float 12.16
No of funds 811
Yield 0.86
Book Value 3.79
U/D Vol ratio 0.7
LTDebt / Equity
Alpha 0.03
Beta 0.34

Dr. Reddy's Laboratories

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 26.7%26.7%26.71%26.71%
Mutual Funds 9.87%10.94%12.84%14.21%
Insurance Companies 12.99%12.22%11.53%10.72%
Foreign Portfolio Investors 27.25%27.29%26.26%25.87%
Financial Institutions/ Banks 0.03%0.02%
Individual Investors 7.59%7.83%8.06%8.22%
Others 15.6%14.99%14.6%14.25%

Dr. Reddy's Laboratories Management

Name Designation
Mr. K Satish Reddy Chairman
Mr. G V Prasad Co-Chairman & Manag. Director
Mr. Leo Puri Independent Director
Mr. Prasad R Menon Independent Director
Ms. Shikha Sharma Independent Director
Mr. Allan Oberman Independent Director
Dr. Bruce L A Carter Independent Director
Ms. Kalpana Morparia Independent Director
Mr. Sridar Iyengar Independent Director
Mr. Arun Madhavan Kumar Independent Director

Dr. Reddy's Laboratories Forecast

Price Estimates


Other Analyst Rating

Dr. Reddy's Laboratories Corporate Action

Date Purpose Remarks
2023-05-10 Audited Results & Final Dividend
2023-01-25 Quarterly Results
2022-10-28 Quarterly Results
2022-07-28 Quarterly Results
2022-05-19 Audited Results & Final Dividend

Dr. Reddy's Laboratories MF Shareholding

Name Amount(cr)
SBI Nifty 50 ETF 149735
HDFC Balanced Advantage Fund Growth 54413
ICICI Prudential Balanced Advantage Fund Growth 46534
UTI Nifty 50 Exchange Traded Fund 38624
ICICI Prudential Bluechip Fund Growth 37016

About Company

Dr. Reddy's Laboratories is a worldwide pharmaceutical corporation headquartered in Hyderabad, Telangana, India. Kallam Anji Reddy, who had worked at the mentor institute Indian Drugs and Pharmaceuticals Limited, started the company. A vast variety of pharmaceuticals are produced and sold by Dr. Reddy in India and other countries. They produce about 190 medications, and 60 active pharmaceutical ingredients (APIs) for the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology products, among other things.

Dr. Reddys Laboratories Ltd- Growth History and Empire Expansion

“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”


With one medicine in a 60-tonne facility close to Hyderabad, Dr. Reddy's launched its business in the Active Pharmaceutical Ingredients (API) category in 1984. It sent its first shipment of Methyldopa medication to West Germany in 1986. It is one of the top three API providers worldwide. They also entered the international market this year with the introduction of the API Methyldopa. In 1987, they received their first USFDA approval for the API Ibuprofen. They have been manufacturing omeprazole, one of the most well-known products, since 1991. They entered Russia, which at the time was the biggest international market, in 1992. To direct research into new cancer and diabetes medicines, the Dr. Reddy's Research Foundation was founded in 1993.

To address the needs of children, teenagers, and women who are at risk in both the economic and social spheres,In 1996, Dr. Reddy's Foundation was founded. They began their biologics business in 1998 with the goal of providing inexpensive access to expensive pharmaceuticals to Indian patients.

As part of their continued global expansion, they bought BMS Laboratories Limited and Meridian Healthcare in the UK in 2002 and released a drug for advanced prostate cancer in India, becoming the first company to introduce Bicalutamide in India. The corporation established Dr. Reddy's Foundation for Health Education and a breast cancer helpline in Mumbai.

In the US, ibuprofen was first made accessible as a generic medication in 2003.

To treat autoimmune diseases and tumors, including non-lymphoma, Hodgkin's introduced the first monoclonal antibody biosimilar in history in 2007. In 2009, revenue in Russia and the CIS exceeded $150 million. In 2012, revenue exceeded USD 2 billion.

By 2016 the business entered the market for branded consumer health goods by purchasing six OTC brands from Ducere Pharma The company just announced its entry into Colombia with a variety of excellent, cost-effective medications for cancer patients.

By purchasing six over-the-counter (OTC) brands from Ducere Pharma in 2016, the company entered the market for branded consumer health products. The business announced its arrival in Colombia with a selection of top-notch, reasonably priced drugs for people with cancer.

In 2017 they expanded their commercial operations in Europe as they introduced the generics portfolio in France. The company's subsidiary Aurigene Discovery Technologies launched a particular initiative to create oral immuno-oncology drugs in 2018. A crucial generic medicine for the treatment of opioid addiction was successfully introduced in the US. 2019 saw the entry of Dr. Reddy's Nutrition into the Indian nutrition market with the launch of Celevida, a ground-breaking product. For the cosmetic and aesthetic area, GLOWRIA, a 40-person, all-female medical representation team, was created. To provide a wide variety of COVID-19 medicines to India as the coronavirus pandemic spread around the globe, they got into significant relationships with international innovation businesses. In the US, they introduced the first generic Otic suspension product. In addition to some anti-allergy brands from the Glenmark portfolio in Russia, Ukraine, Kazakhstan, and Uzbekistan, they bought specific business divisions of Wockhardt in India. They joined the Science Based Targets program as the first pharmaceutical business in India.

Corporate Social Responsibility Information

The Company may carry out the following CSR-related projects or programs:

  • Fighting against hunger, poverty, and malnutrition, encouraging preventative care, cleanliness, and the provision of safe drinking water.
  • Projects to improve livelihoods and promote education, including special education and employment-enhancing vocation skills, particularly among children, women, older people, and people with disabilities.
  • Maintaining the quality of soil, air, and water while ensuring environmental sustainability, ecological balance, animal welfare, protection of flora and fauna, and agroforestry.
  • Education to promote Olympic, paralympic, and rural sports that are recognized nationwide.
  • Contribution to the prime minister's national relief fund, the PM CARES Fund, or any other fund established by the central government for the socio-economic development, relief, and welfare of the scheduled caste, tribes, other underprivileged classes, minorities, and women
  • Contributions to public-funded universities in the field of technology, national laboratories, and autonomous bodies engaged in conducting research in the fields of atomic energy, science, and technology
  • Contributions to incubators or research and development projects in the fields of science, technology, engineering, and medicine, funded by the Central Government or State Government or Public Sector Undertaking or any agency of the Central Government or State Government
  • Contributions to publicly funded research universities, national laboratories, and autonomous organizations conducting research in the fields of atomic energy, science, technology, biotechnology, pharmaceuticals, electronics, and information, as well as defense, agricultural, scientific, and industrial research, engineering, and medicine and listed in Schedule VII of the Act and its implementing regulations
  • projects for rural development.
  • Construction in slum areas.
  • Any other activities or subjects listed in Schedule VII of the Companies Act, 2013 (the Act) and the rules made thereunder, as amended from time to time, and circulars/notifications issued by statutory authorities.
  • Disaster management, including relief, rehabilitation, and reconstruction activities.

Dr. Reddy's Laboratories FAQs

What is Share Price of Dr. Reddy's Laboratories ?

Dr. Reddy's Laboratories share price is ₹4666 As on 10 June, 2023 | 12:17

What is the Market Cap of Dr. Reddy's Laboratories ?

The Market Cap of Dr. Reddy's Laboratories is ₹77723 Cr As on 10 June, 2023 | 12:17

What is the P/E ratio of Dr. Reddy's Laboratories ?

The P/E ratio of Dr. Reddy's Laboratories is 17.2 As on 10 June, 2023 | 12:17

What is the PB ratio of Dr. Reddy's Laboratories ?

The PB ratio of Dr. Reddy's Laboratories is 3.3 As on 10 June, 2023 | 12:17

Q) How to buy Dr. Reddys Laboratories Ltd shares?

Ans - You can easily buy the shares of Dr. Reddys Laboratories Ltd, by registering at 5Paisa and by setting up a Demat Account in your name.

Q) What is the 52-week high and low price of shares of Dr Reddys Laboratories Ltd.

Ans – Dr Reddys Laboratories Ltd shares have a 52-week high of Rs 5,614.60 and a 52-week low of Rs 3,654.

Q) What is the Return of Equity on shares of Dr Reddys Laboratories Ltd for the past 1 year?

Ans – The Return on Equity on shares of Dr Reddys Laboratories Ltd is 11.8% for last year.

Q) What is the face value of a share of Dr Reddys Laboratories Ltd?

Ans – The face value of a share of Dr Reddys Laboratories Ltd. is INR 5 per share.

What is Dr Reddys Laboratories's stock price CAGR?

Dr Reddys Laboratories stock price CAGR for 10 Years stands at 12%, 5 Years at 8%, 3 Years at 20%, and 1 Year at -2%.

What is the ROE of Dr Reddys Laboratories?

The ROE of Dr Reddys Laboratories is 11%.

Is Dr Reddys Laboratories a good investment?

Dr Reddy's Laboratories has an operating revenue of Rs. 20,442.10 Cr. on a trailing 12-month basis. Annual revenue growth of 7% is good, Pre-tax margin of 15% is great. As per analysts rating in the last 6 months, the recommendation is to HOLD Dr Reddys Laboratories.

Who is the CEO of Dr Reddys Laboratories

Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019.

What is the Profit before tax of Dr. Reddys Laboratories Ltd stock?

Profit before tax of Dr. Reddys Laboratories Ltd stock for the quarter ended March 2022 is Rs 567 crores.


Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number